Alyssa M. Peckham, Pharm.D., BCPP

Assistant Professor

Midwestern University

College of Pharmacy
Department of Pharmacy Practice
Cholla Hall, Office 201-1

19555 N 59th Ave
Glendale, AZ 85308

Office: (623) 572-3526


Doctor of Pharmacy University of Rhode Island 2014
Board Certified Psychiatric Pharmacist Board of Pharmacy Specialties 2016


Prescription drug abuse

Currently engaging in research related to gabapentin abuse. Thus far, we have estimated the prevalence of gabapetnin abuse and resulting medical consequences. We have also conducted a state-by-state survey of gabapentin lesiglation and regulation, and have theorized potential avenues of unintended harm in the absense of a national, unified approach to tighter regulation. Future projects building upon this research are listed below.

Research projects

Gabapentin: FAERS analysis, fractal analysis, economic analysis, review of efficacy, prescriber awareness survey

Naloxone: Assessing change in OOKS, OOAS, and DDPPQ scores amongst multidisciplinary healthcare students at two academic institutions

Select Publications

  1. Peckham AM, Nicewonder JA. VMAT2 inhibitors for tardive dyskinesia - Practice implications. Journal of Pharmacy Practice. 2018 Feb 18. doi:
    10.1177/0897190018756512. [Epub ahead of print]

  2. Fairman KA, Davis LE, Peckham AM, Sclar DA. Diagnoses of cardiovascular disease or substance addiction/abuse in US adults treated for ADHD with stimulants or atomoxetine: Is use consistent with product labeling? Drugs Real World Outcomes. 2018 Jan 5. doi: 10.1007/s40801-017-0129-2. [Epub ahead of print]

  3. Peckham AM, Fairman KA, Sclar DA. Call for increased pharmacovigilance of gabapentin. BMJ. 2017 Nov 30;359:j5456. doi: 10.1136/bmj.j5456.

  4. Early NK, Peckham AM, Fairman KA, Sclar DA. Prevalence of depression and receipt of antidepressant pharmacotherapy among patients with Parkinson's disease: A national assessment of U.S. office-based physician visits. Journal of Parkinsonism and Restless Legs Syndrome. 2017 Nov 16;7:79-84.

  5. Peckham AM, Niculete ME, Steinberg H, Boggs DL. A survey of prescribers' attitudes, knowledge, comfort, and fear of consequences related to an opioid overdose education and naloxone distribution program. J Public Health Manag Pract. 2017 Oct 27. doi: 10.1097/PHH.0000000000000668. [Epub ahead of print]

  6. Peckham AM, Fairman KA, Sclar DA. Policies to mitigate nonmedical use of prescription medications: How should emerging evidence of gabapentin misuse be addressed? Expert Opin Drug Saf. 2017 Oct 6. doi: 10.1080/14740338.2017.1390081. [Epub ahead of print]

  7. Peckham AM, Fairman KA, Sclar DA. All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: A retrospective cohort analysis of a commercially insured US population. Drug Saf. 2018 Feb;41(2):213-28. doi: 10.1007/s40264-017-0595-1.

  8. Peckham AM, Fairman KA, Sclar DA. Prevalence of gabapentin abuse: Comparison with agents with known abuse potential in a commercially insured US population. Clin Drug Investig. 2017 Aug;37(8):763-73. doi: 10.1007/s40261-017-0530-3.

  9. Fairman KA, Peckham AM, Sclar DA. Diagnosis and treatment of ADHD in the United States: Update by gender and race. J Atten Disord. 2017 Feb 1:1087054716688534. doi: 10.1177/1087054716688534. [Epub ahead of print]

  10. Boggs DL, Peckham A, Boggs AA, Ranganathan M. Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the ''weed,'' a pharmacodynamic discussion. Ment Health Clin [Internet]. 2016 Nov;6(6):277-84. doi: 10.9740/mhc.2016.11.277.

  11. Peckham AM, Boggs, DL. The overdose education and naloxone distribution program at a VA hospital. Fed Pract. 2016 Nov 23;33(11):28-31.